White and Williams Represents Appili Therapeutics in Commercial Licensing Agreement with Saptalis Pharmaceuticals
White and Williams represented Appili Therapeutics, Inc. (TSXV: APLI) (“Appili”) in the negotiation and execution of a license agreement with Saptalis Pharmaceuticals LLC (“Saptalis”) for the commercialization of Appili’s liquid suspension reformulation of the antibiotic metronidazole, ATI-1501. Appili is a Canadian-based biopharmaceutical company that is focused on anti-infective drug development; Saptalis is a New York-based specialty pharmaceuticals company. Under the agreement, Appili will now be able to receive royalty payments on the sale of ATI-1501 in the United States, while Saptalis will be responsible for overseeing the regulatory review, manufacturing and preparation of the U.S. commercialization of ATI-1501. The novel drug, in an oral liquid form rather than the current table for, is a prescribed antibiotic that is used to treat parasitic and anaerobic bacterial infections. There is a market potential of more than 600,000 patients in the U.S. alone, many who have trouble with the antibiotic in its current form.
Corporate partner Ryan Udell led the representation of Appili, with assistance from Corporate associate Adam Chelminiak.